FLT3 and acute myeloid leukemia: Two independent studies by Bhatnagar et al. and Stiff et al. demonstrated that poor outcomes among NHB patients with AML are contradictorily associated with favorable-risk molecular profiles, including NPM1 mutations and wild-type FLT3 [3,5].